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Abstract
While cancer stem cells are well established in certain hematologic and solid malignancies, their existence in T cell
lymphoma is unclear and the origin of disease is not fully understood. To examine the existence of lymphoma stem cells, we
utilized a mouse model of anaplastic large cell lymphoma. Established NPM-ALK+ lymphomas contained heterogeneous
cell populations ranging from mature T cells to undifferentiated hematopoietic stem cells. Interestingly, CD4−/CD8− double
negative (DN) lymphoma cells aberrantly expressed the T cell receptor α/β chain. Serial transplantation of sorted CD4/CD8
and DN lymphoma subpopulations identified lymphoma stem cells within the DN3/DN4 T cell population, whereas all other
subpopulations failed to establish serial lymphomas. Moreover, transplanted lymphoma DN3/DN4 T cells were able to
differentiate and gave rise to mature lymphoma T cells. Gene expression analyses unmasked stem-cell-like transcriptional
regulation of the identified lymphoma stem cell population. Furthermore, these lymphoma stem cells are characterized by
low CD30 expression levels, which might contribute to limited long-term therapeutic success in patients treated with anti-
CD30-targeted therapies. In summary, our results highlight the existence of a lymphoma stem cell population in a NPM-
ALK-driven CD30+ mouse model, thereby giving the opportunity to test innovative treatment strategies developed to
eradicate the origin of disease.
Introduction
The identity of so-called cancer stem cells in malignant
diseases is subject to debate [1–3]. As the clinical response
of solid and hematological tumors to traditional treatments
has been attributed to this small subpopulation of cells, the
importance of characterizing them is crucial [4, 5]. The
concept of a limited pool of tumor stem cells with capacity
for self-renewal and plasticity is well established in certain
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malignancies such as breast cancer, colorectal cancer, brain
cancer, and leukemia [6–10]. However, identification of the
cell-of-origin of B cell lymphomas is limited and data on
the understanding of initiation and maintaining of T cell
lymphoma, especially for anaplastic large cell lymphoma
(ALCL) are limited [11, 12]. ALCL belongs to a group of
aggressive Non-Hodgkin lymphomas and was first descri-
bed in 1985 by Stein et al., who characterized it as a
cohesive proliferation of large pleomorphic cells expressing
CD30 [13]. In 60% of patients a translocation t(2;5)(p23;
q35) is found, which generates a fusion gene between
nucleophosmin (NPM) and the receptor tyrosine kinase
gene anaplastic lymphoma kinase (ALK), thereby leading to
constitutive activation of the ALK tyrosine kinase [14, 15].
Molecular characterization of lymphoma stem cells and
their activated pathways in ALCL may help in the design of
targeted treatment strategies for the ALCL patient popula-
tion [16–19]. It is a well-established principle, that therapies
which eradicate the cancer stem cell population, assure
higher long-term response with a lower recurrence rate than
treatment regimens that focus on tumor mass reduction and
may not affect cancer stem cells.
In this work, we aimed to identify and characterize the
lymphoma stem cell population in a murine ALCL-like
model [20]. Within this model, NPM-ALK is expressed in a
lineage-specific manner in early T cells leading to char-
acteristic CD30 expression and large cell cytology in a
heterogeneous malignant T-cell population [20].
In this study, we identify and characterize a distinct,
malignant T-cell subpopulation of CD30+ NPM-ALK dri-
ven lymphoma as well as their stem cell potency measured
by their ability to establish lymphoma in serially
transplanted mice.
Methods
Constructs, cell culture and virus generation
For virus production, Phoenix E ecotropic packaging cells
(kind gift from G. Nolan, Stanford, CA) were transiently
transfected with the retroviral construct MSCV-STOP-
NPM-ALK-IRES-EGFP (MSNAIE) [20] and viral super-
natants were collected as described previously [21, 22].
Retroviral titers were determined by transduction of NIH/
3T3 cells (DSMZ) as described previously (Supplementary
Fig. 1) [23].
Reagents
Recombinant murine Interleukin-3 (IL-3), IL-6, and SCF
were purchased from R&D Systems (Minneapolis, MN,
USA). Fetal calf serum, 5-Flouorouracil, and Polybrene was
from Sigma-Aldrich (St. Louis, MO, USA). DMEM (Dul-
becco’s Modified Eagle Medium) and ES cell FBS (fetal
bovine serum) was from Thermo Scientific (Waltham,
USA). Lipofectamine 2000 was purchased from Invitrogen
(Carlsbad, CA, USA).
Mice
The Lck-Cre mouse line (B6.Cg-Tg(Lck-cre)548Jxm/J) was
obtained from Jackson Laboratory (Bar Harbor, Maine,
USA). All mice were backcrossed to a C57BL/6 back-
ground for more than 10 generations. The animals were
housed in a special caging system with autoclaved food and
acidified water at the University of Freiburg. All procedures
were performed in accordance with national and institu-
tional guidelines for animal care and experiments.
Transplantation assays
Murine bone marrow (BM) was collected from Lck-Cre-
transgenic and control mice and infected as described pre-
viously [21, 24]. Briefly, 12-week-old male donor mice
were treated once with 5-Fluorouracil (150 mg/kg) at day
−4 and BM cells were harvested from tibia and femur.
After preincubation overnight in BM media (DMEM, 30%
FBS, 10 ng/ml mIL-3, 10 ng/ml mIL-6, 50 ng/ml mSCF),
BM cells were infected with retroviral supernatant as
described previously [23]. Infection efficiency was deter-
mined by flow cytometric analysis of EGFP expression.
Female C57BL/6 wildtype recipient mice were irradiated
with 850 rad and transplanted with 5 × 104 infected cells/
2 × 105 total cells via tail vein injection (Supplementary
Fig. 2A). For serial transplantations, mice were irradiated
sublethally with 450 rad and 2.5 or 1.5 × 103 EGFP positive
cells were injected. Peripheral blood was taken at the
indicated time points and WBCs were measured using an
automated counter (ABC scil vet). Transplanted mice were
monitored for signs of disease and sacrificed and analysed
on observing clinical signs.
Flow cytometry analysis and cell sorting
Flow cytometric analysis was performed as described [25].
The BD LSR Fortessa and FACS Aria III (BD Biosciences,
Heidelberg, Germany) were used for analyzing and sorting.
Antibodies used to stain cell surface proteins were: anti-
mouse CD4 (GK1.5), CD8a (53-6.7), CD11b (Mac-1, M1/
70), CD25 (PC61.5), CD30 (mCD30.1), CD44 (IM7),
CD45R/B220 (RA3-6B2), CD45 (30-F11), CD90.2
(THY1.2, 53-2.1), CD117 (c-KIT, 2B8), CD127 (IL-7Ra,
A7R34), GR1 (Ly-6G, RB6-8C5), SCA1 (D7), TCR-α/β
(IP26) and TER119 (TER119) and the corresponding iso-
types, were obtained from BD Biosciences or eBiosciences
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(Frankfurt am Main, Germany). For intracellular staining
cells were treated with Cytofix Buffer and Perm Buffer III
(both from BD Biosciences) according to the manu-
facturer’s protocol. Antibodies used to perform intracellular
staining were Ki67 (SolA15) (eBiosciences) and ALK
(D5F3) (Cell signaling, Frankfurt am Main, Germany).
Gene expression analysis
RNA extraction was performed as described previously [25]
as was generation of Microarray data [26]. Regulated genes
were identified using a linear-based model, limma R pack-
age. The threshold for significance was set to an adjusted p
value < 0.01 (Benjamini Hochberg).
Accession numbers
The accession number for the microarray data reported in
this paper is GEO ID: GSE132267. Microarray data for
comparison of ALCL, EL4 and Tx17 cells were submitted
to Gene Omnibus database (GEO accession number
pending).
Statistical analysis
A two-sided Student’s t test was used for statistical ana-
lyses. Mean ± standard deviation were analysed as indi-
cated. The survival curves were produced using a log-rank
(Mantel-Cox) test. P values were defined as indicated
in figure legends: *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
Results
ALCL stem cells derive from CD4−/CD8− double
negative lymphoma T cells
MSNAIE-infected, Lck-Cre BM transplanted, recipient
mice develop ALCL-like malignancies with enlarged lym-
phatic organs (thymus, spleen, lymph nodes), BM infiltra-
tion, a distinct T cell phenotype and undifferentiated T cells
within the EGFP positive lymphoma population (Fig 1a–c,
Supplementary Figs. 1 and 2) [20]. Staining of the T cell
subpopulations demonstrated high NPM-ALK expression in
immature CD4−/CD8− double negative (DN) T cells and
undifferentiated CD4+/CD8+ double positive T cells
(Supplementary Fig. 3A). Immunophenotyping for the
proliferation marker Ki-67 revealed high expression in the
NPM-ALK+ T cells (Supplementary Fig. 3A). Comparison
of transcriptional analyses demonstrated an upregulation of
Bcl6 and Perforin in the ALCL-like lymphoma compared
with other murine T cell lymphomas/leukemias (EL4 cell
line and Notch-driven ALL), whereas this was not the case
for Cebpb, Ptpn12, and Serpina1 (Supplementary Fig. 3B).
Interestingly, the CD4−/CD8− DN lymphoma population
aberrantly expressed the T cell receptor (TCR) α/β chain,
which may allow these early T cells to establish a systemic
lymphoma (Fig. 1d). Therefore, we hypothesized that the
lymphoma stem cell population is contained within this
early T cell population. To prove our hypothesis, we per-
formed secondary transplantations with different lymphoma
subpopulations depending on their CD4/CD8 T cell status.
Therefore, we sorted primary ALCL-like lymphomas from
the thymus for CD4 and CD8 expression (Fig. 1e) and
transplanted 2500 cells of the isolated subpopulations into
sublethally irradiated recipient animals. None of the CD4+/
CD8+, CD4+/CD8− nor CD4−/CD8+ cell populations were
able to induce lymphoma, whereas the CD4−/CD8− DN
lymphoma population exclusively established T cell lym-
phoma in the secondary recipient mice with a median sur-
vival of 68 days (Fig. 1f). Similar to the primary
transplanted animals, the serial transplanted animals
developed significant splenomegaly, enlarged thymus, BM
infiltration and increased white blood cell counts compared
with animals transplanted with the other CD4/
CD8 subpopulations (Fig. 1g–i). Flow cytometric analyses
of lymphomas from CD4/CD8 DN lymphoma cell-
transplanted mice showed high EGFP expression in all
lymphatic organs and the BM (Supplementary Fig. 4),
which indicates lymphoma induction via NPM-ALK
expression.
These results highlight the existence of a lymphoma
stem cell population in our murine ALCL-like, which
has the ability to induce serial malignancies in mice and is
CD4−/CD8− DN supportive of a primitive origin.
Serially transplanted CD4−/CD8− lymphoma cells
differentiate into mature T cells
Further immunophenotypic characterization of lymphomas
induced by serially transplantation of CD4−/CD8− T cells
of primary murine ALCL-like lymphomas demonstrates a
pure T cell phenotype (Fig. 2a). Interestingly, all of the
CD4/CD8 T cell subpopulations: single positive CD4+/
CD8−, CD4−/CD8+ as well as double positive CD4+/CD8+
cells, are detectable by flow cytometry in all organs ana-
lysed, although the main lymphoma population consists of
DN T cells (Fig. 2b). The ability of the initially transplanted
CD4−/CD8− T cells to differentiate in distinct CD4/CD8
T cell subpopulations supports the hypothesis of lymphoma
stem cell presence within the CD4−/CD8− T cell sub-
population that maintains the ability to differentiate into
mature T cells.
Quantitative analysis between the EGFP positive T cell
lymphoma subpopulations of primary and CD4−/CD8−
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transplanted secondary mice exhibited slight differences in
T cell distribution: thymic lymphomas developing in sec-
ondary CD4−/CD8− lymphoma T cell-transplanted mice
contained a larger amount of CD4−/CD8− DN lymphoma
cells (58.7% vs. 48.0%; p= 0.03) than the primary thymic
lymphomas developing in the donors, whereas CD4+/CD8+
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double positive lymphoma cells were represented to a
greater extent in primary thymic lymphomas compared with
those developing in secondary CD4−/CD8− transplanted
mice (29.4% vs. 15.7%; p= 0.0007) (Fig. 2c, left panel).
Analyses of BM from primary and secondary CD4−/CD8−
lymphoma cell-transplanted animals revealed no differences
in the CD4/CD8 distribution of lymphoma cells (Fig. 2c,
right panel). Therefore, our data show, that serially trans-
planted CD4−/CD8− lymphoma stem cells have the
potential to partly differentiate and give rise to mature T cell
subpopulations.
Primary MSNAIE Lck-Cre induced lymphomas
contain a heterogeneous cell population ranging
from undifferentiated hematopoietic stem cells to
mature T cells
Having identified lymphoma stem cells in the CD4−/CD8−
cell population of lymphomas developing in primary
MSNAIE Lck-Cre mice, we set out to further characterize
this distinct cell population. Hence, the CD4−/CD8− DN
T cell lymphoma population of primary MSNAIE-infected
Lck-Cre transgenic BM transplanted mice was compre-
hensively immunophenotyped. To differentiate in the EGFP
(NPM-ALK) positive population between T cell DN stages
(DN1–DN4) and immature LSK (lineage− SCA1+cKIT+),
MP (multipotent progenitors, lineage− SCA1−cKIT+) and
CLP (common lymphoid progenitor, lineage− SCA1low
cKITlow Il7Rα+) populations, cells were stained for T cell
markers (CD25 and CD44) as well as stem and progenitor
cell markers (cKIT, SCA1, and Il7Rα) (Fig. 3a, b, Sup-
plementary Fig. 5). As shown in Fig. 3c, the composition of
primary EGFP+ thymic and BM lymphoma cells from
MSNAIE-infected Lck-Cre transgenic BM transplanted
mice was heterogeneous: regarding the CD4/CD8 distribu-
tion (Fig. 3c, left pie charts), the majority of cells belong to
the CD4−/CD8− DN population, whereas all other CD4/
CD8 subgroups were detected with CD4+/CD8− single
positive cells being the minor population. Interestingly, in-
depth immunophenotypic analyses of the CD4−/CD8− DN
population (Fig. 3c, right pie charts) identified T cell DN
stages 1–4 as well as lymphatic precursors (CLP), multi-
potent progenitors (MP), and hematopoietic stem cells
(LSK). These results showed that the DN T cell pool is
considerably heterogeneous and consists of different
immature cell populations. It thereby points to a necessity to
further define and specify the lymphoma stem cells within
these immunophenotypically different cell populations.
Lymphoma stem cells reside within the DN3/DN4
T cell population, but not the DN1/DN2 population
To further investigate and specify the origin of the lym-
phoma stem cell population we performed multiple serial
transplantation experiments, where we isolated and sorted
DN1, DN2, DN3, and DN4 T cell subpopulations from
established tumors (Fig. 4a) and transplanted 1500 cells
into sublethally irradiated recipient mice. Interestingly,
development of serial lymphomas was only detected in
mice, which were transplanted with DN3 or DN4 lym-
phoma T cells, whereas sorted DN1 or DN2 lymphoma
T cells failed to establish serial disease (p= 0.018;
Fig. 4b). Immunophenotypic analyses of serial lymphomas
induced following transplantation of DN3 or DN4 lym-
phoma cells showed a range of CD4/8 subpopulations
(CD4−/CD8− DN T cells as well as CD4+ and CD8+ single
positive cells and CD4+/CD8+ double positive cells) as
observed previously (Fig. 4c, d). These results imply that
the DN3/DN4 population contains lymphoma stem cells,
which are responsible for induction of serially transplan-
table disease and give rise to differentiated cells. Staining
for early T cell markers (CD25 and CD44) demonstrated
the co-occurrence of DN3 and DN4 cells. Dedifferentiation
of transplanted DN3 cells to a DN1/2 status was not
observed (Fig. 4e).
Taken together, serial transplantation with sorted DN1-4
lymphoma T cell subpopulations identified the existence of
lymphoma stem cells within the DN3/DN4 T cell popula-
tion. In addition, these lymphoma stem cells are able to
differentiate and give rise to mature lymphoma T cells.
Fig. 1 ALCL stem cells derive from CD4−/CD8− double negative
lymphoma T cells. a A Kaplan–Meier survival curve of primary
transplanted mice. 50,000 EGFP positive MSNAIE Lck-Cre transgenic
or wildtype BM cells were injected i.v. into lethally irradiated
(8500 rad) C57Bl6 recipient mice. Median survival: 130 days.
n (wildtype)= 15, n (Lck-Cre)= 22. b Comparison of spleen and
thymi weights of control (n= 9) and MSNAIE Lck-Cre transplanted
mice (n= 15). c Flow cytometric dot plots of EGFP positive cells in
the thymus of one representative MSNAIE Lck-Cre BM transplanted
mouse stained with anti-B220, anti-GR1, anti-CD11b, anti-Thy1.2,
anti-CD4, and anti-CD8. d Flow cytometric dot plots of lymphatic
organs and BM of primary MSNAIE Lck-Cre BM transplanted mice
stained for anti-CD4, anti-CD8, and TCR α/β. e Sorting strategy for
secondary transplantation of EGFP positive T cell subpopulations.
Single cell suspensions of the thymus were stained with anti-CD4
and anti-CD8 and sorted for the four T cell subpopulations.
f Kaplan–Meier survival curve of secondary transplanted mice. 2500
EGFP positive lymphoma cells (CD4/CD8 subpopulation) were
injected i.v. into sublethally irradiated (4500 rad) C57Bl6 recipient
mice. Median survival of CD4−/CD8− transplanted mice: 68 days n=
6. g White blood counts (WBC) at death of peripheral blood isolated
from CD4−/CD8− transplanted recipients or at day 120 in case of the
other CD4/8 subgroup. Six mice in each subgroup were analysed.
h WBC counts over time of Tx of serial CD4/CD8 lymphoma sub-
population transplanted mice. Six mice in each subgroup were ana-
lysed. i Comparison of spleen weights of serial CD4/CD8 lymphoma
subpopulation transplanted mice at death (CD4−/CD8−) or at the end
of Tx (other subgroups). Six mice in each subgroup were analysed.
***p < 0.001. Data are represented as means ± SD.
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The gene expression signature of the lymphoma
stem cell population reveals a stem-cell-like
transcriptional profile
To further characterize the lymphoma stem cell population,
we performed Affymetrix-based global gene expression
analysis of the sorted lymphoma cell subsets. We hypo-
thesized that lymphoma stem cells might have a gene
expression pattern, which resembles hemopoietic stem cells.
Indeed, microarray analyses showed not only a high simi-
larity of gene expression patterns between DN3 and DN4
lymphoma T cell subpopulations but importantly also
resembled stem cell (LSK cells) gene expression profiles as
seen in the heatmap (Fig. 5a, Supplementary Fig. 6A).
Principle component analysis separated lymphoma T cell
subpopulations DN1–DN4 according to their variance not
Fig. 2 Serially transplanted CD4−/CD8− lymphoma cells differ-
entiate into mature T cells. Representative flow cytometry profiles of
single cell suspensions of lymphatic organs: thymus (Thy), spleen
(Spl), lymph node (LN) and bone marrow (BM) of CD4−/CD8−
lymphoma subpopulation transplanted mice. a EGFP+ lymphoma cells
stained for anti-B220, anti-GR1, anti-CD11b, and anti-Thy1.2 show a
clear T cell phenotype. b EGFP+ lymphoma cells stained for anti-CD4
and anti-CD8 demonstrate the ability to differentiate into mature T cell
subpopulations. c Quantitative analysis of CD4/CD8 lymphoma T cell
subpopulation distribution within the thymus and bone marrow of
primary (black bars) and secondary (white bars) transplanted mice
shows the differentiation capability of CD4−/CD8− DN subpopula-
tions. Six mice in each subgroup were analysed. *p < 0.05; ***p <
0.001. Data are represented as mean+ SD.
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only of the most 1000 variable genes (Fig. 5b) but also all
analysed genes (Supplementary Fig. 6B), thereby sub-
stantiating our hypothesis as DN3 and DN4 cluster together
and are significantly separate from DN1 and DN2 popula-
tions. Using a Venn diagram, we were able to show
significantly more up- and downregulated genes in DN3/
DN4 lymphoma T cell subpopulations in comparison to the
DN1/DN2 lymphoma T cell subpopulation vs. LSK cells
with a cut-off < 0.01 (Fig. 5c, d), which might suggest a
higher similarity of expression profiles of DN3/DN4
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lymphoma T cells and LSK cells. Gene set enrichment
analyses for genes, which are downregulated in hemato-
poietic stem cells revealed a stem cell signature in DN3
lymphoma T cells, whereas for example, the DN1 lym-
phoma T cell population did not show similarity to tran-
scriptional profiles of hematopoeitic stem cells (Fig. 5e).
The most deregulated genes of the gene set enrichment
analysis in 5E and their expression can be seen in Fig. 5f.
To summarize, bioinformatic analyses of Affymetrix-
based global gene expression data clearly separated DN3
and DN4 lymphoma T cell subpopulations from DN1 and
DN2 lymphoma T-cell subpopulations. Interestingly, heat-
map analyses as well as Venn diagram and gene set
enrichment analyses suggest that the DN3 and DN4 lym-
phoma T cells exhibit a gene expression signature resem-
bling that seen in LSK cells which show more stem-like
features than the DN1 lymphoma T cells, although being
immunophenotypically more differentiated.
The lymphoma stem cell population is characterized
by relatively low CD30 expression levels
CD30 expression on human ALCL cells is not only a
diagnostic tool but is also exploited for targeted therapeutic
approaches whereby the antibody-drug conjugate Brentux-
imab vedotin [27] binds and eliminates CD30-positive cells
[28, 29]. However, resistance can develop due to down-
regulation of CD30 expression on tumor cells [30, 31] and
hence durable remissions are limited in ALCL patients
treated with single-agent brentuximab vedotin. Therefore,
one may hypothesize, that CD30 expression on lymphoma
stem cells might facilitate long-term treatment response.
To test this hypothesis, we analysed the CD30 expression
level on lymphoma cells in the ALCL-like mouse model.
Interestingly, although the T cell lymphoma showed overall
high CD30 expression [20], the level differed between the
distinct lymphoma T cell subpopulations: focusing on T cell
lymphoma subpopulations according to CD4 and/or CD8
expression, the DN CD4−/CD8− as well as the single
positive CD8+ lymphoma subpopulation showed sig-
nificantly lower CD30 expression compared with the double
positive CD4+/CD8+ and single positive CD4+ lymphoma
population (Fig. 6a, b). As our previous data indicate that
the lymphoma stem cell population is immunophenotypi-
cally included in the DN3/DN4 lymphoma T cell sub-
population, we analysed CD30 expression levels on
different DN stages of lymphoma cells. As shown in
Fig. 6c, DN3 and DN4 T cell lymphoma subpopulations in
particular showed significantly lower CD30 expression
compared with DN1 and DN2 cells (Fig. 6c, d). It is
noteworthy, that DN4 lymphoma cells show even lower
CD30 expression than the single positive CD8+ lymphoma
subpopulation and this phenomenon was consistently seen
on lymphoma cells extracted from thymus, lymph node or
spleen (ΔMFI (DN4)= 259 vs. ΔMFI (CD8+)= 437; p=
0.003; Supplementary Fig. 7). We hypothesized that the
alteration in CD30 expression is caused by transcriptional
regulation. To verify our hypothesis, we analyzed well
known CD30 transcriptional regulators of the activating
protein-1 for their expression levels in the different lym-
phoma subpopulations and were indeed able to show, that
they are downregulated in the DN3/4 lymphoma stem cell
population compared with CLP, DN1, and DN2 lymphoma
subpopulation (Fig. 6e) [32, 33].
These results imply, that the lymphoma stem cell DN3/
DN4 population is characterized by relatively low CD30
expression levels due to transcriptional regulation, which
might contribute to limited long-term response in patients
treated with anti-CD30-targeted therapies.
Our results therefore highlight the existence of a lym-
phoma stem cell population originating from the DN3/DN4
lymphoma T cell population in a relevant NPM-ALK
positive CD30-expressing ALCL-like mouse model, which
might contribute to treatment evasion due to low CD30
expression levels.
Discussion
In this study, we have identified and specified the existence
of a lymphoma stem cell population using a retroviral
murine BM transplantation model resembling human ALCL
in terms of CD30 expression and large cell cytology
whereas other morphologic characteristics differ from the
human pathology. Although the murine tumor cells do not
show the characteristic hallmark cells and variants (like
doughnut cells and horse shoe or kidney shaped nuclei)
[34], we believe that the large cell morphology with open
chromatin and prominent nucleoli reproduced the human
Fig. 3 Primary MSNAIE Lck-Cre induced lymphomas contain a
heterogeneous cell population ranging from undifferentiated
hematopoietic stem cells to mature T cells. a Representative flow
cytometry profiles of EGFP+ thymus and BM cells of MSNAIE Lck-Cre
transgenic BM transplanted mice. Cells were stained for anti-CD4, anti-
CD8, anti-CD25, and anti-CD44. b Representative flow cytometry
profiles of EGFP+ lineage negative (lin-) thymus and BM cells of
MSNAIE Lck-Cre transgenic BM transplanted mice. Cells were stained
for hematopoetic stem cell and lymphatic precursor proteins anti-SCA1,
anti-cKIT, and anti-IL7Rα. LSK: lineage−SCA1+cKIT+; MP multi-
potent progenitors, lineage−SCA1−cKIT+; CLP common lymphoid
progenitors, lineage−SCA1lowcKITlowIl7Rα+. c Pie chart of EGFP+
T cell subpopulations differentiated for CD4 and CD8 (left charts) of
thymus and BM of five independent MSNAIE Lck-Cre transgenic BM
transplanted mice. Distribution over the different cell types within the
EGFP+ CD4−/CD8− DN lymphoma subpopulation are shown from five
independent diseased animals on the right. CLP common lymphoid
progenitors, lineage−SCA1lowcKITlowIl7Rα+, LSK lineage−SCA1+
cKIT+, MP multipotent progenitors, lineage−SCA1−160cKIT+.
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counterpart well. However, mice with advanced disease
show diffuse pattern of infiltration like seen in advanced
human disease. Histophathologic analyses of mice with
diffuse lymph node involvement and splenic disease did not
show sinusoidal pattern of infiltrated lymph nodes as
observed in human ALCL. As the pattern of lymph node
involvement changes due the course of disease, different
lymph node infiltration patterns may be observed in earlier
Fig. 4 Lymphoma stem cells reside within the DN3/DN4 T cell
population, but not the DN1/DN2 population. a Strategy for sec-
ondary transplantation of lymphoma subpopulations: 1500 EGFP
positive CD4−/CD8− double negative lymphoma T cells of stages
DN1 to DN4 were injected i.v. into subl-ethally irradiated (4500 rad)
C57Bl6 recipient mice. b Kaplan–Meier survival curve of serially
transplanted mice. Median survival: DN3 transplanted mice: 41 days,
DN4 transplanted mice: 50 days. Representative flow cytometry pro-
files of lymphatic organs, thymus (Thy), spleen (Spl), lymph node
(LN) and bone marrow (BM) of DN3 (c, e) and DN4 (d) transplanted
mice stained for anti-CD4, anti-CD8, anti-CD44, and anti-CD25. *p <
0.05; ***p < 0.001.
3250 S. Kreutmair et al.
Fig. 5 The gene expression signature of the lymphoma stem cell
population reveals a stem-cell-like transcriptional profile. a Heat-
map comparing gene expression levels of DN1-DN4 lymphoma sub-
populations with the primitive LSK population. Color scale represents
the raw Z-score mRNA intensity value. b Principle component ana-
lysis (PCA) separating lymphoma subpopulations DN1–DN4 accord-
ing to their variance of all genes analysed by microarray. PCA was
performed on the top 1000 variable genes based on the Median
Absolute Deviation (MAD). c Venn diagram showing significantly
upregulated genes comparing DN1/DN2 and DN3/DN4 lymphoma
subpopulations vs. LSK cells analysed by microarray with a q value
cut-off < 0.01. d Venn diagram showing significantly downregulated
genes comparing DN1/DN2 and DN3/DN4 lymphoma subpopulations
vs. LSK cells analysed by microarray with a q value cut-off < 0.01.
e Signature enrichment plot comparing DN3 vs. DN1 lymphoma
subpopulations for genes downregulated in CD133+ hematopoietic
stem cells compared with CD133- cells (M6905 gene set) analysed by
microarray. FDR q value= 0.027. f Heatmap comparing DN3 vs. DN1
lymphoma subpopulations for expression levels of genes down-
regulated in hematopoietic stem cells analysed by microarray. Color
scale represents raw Z-score mRNA intensity values (red= high
expression, blue= low expression).
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Fig. 6 The lymphoma stem cell population is characterized by low
CD30 expression levels. a CD30 expression levels of the indicated
EGFP+ T cell subpopulations differentiated for CD4 and CD8 of
lymphoma cells isolated from MSNAIE Lck-Cre transgenic BM
transplanted mice. Δ Mean fluorescence intensity (MFI)=MFI of anti-
CD30 stained sample minus MFI isotype n= 14. b Representative
flow cytometry histograms of EGFP+ lymphoma cells differentiated
for CD4 and CD8 and stained for anti-CD30 isolated from MSNAIE
Lck-Cre transgenic BM transplanted mice. c CD30 expression
levels on the indicated EGFP+ T cell lymphoma subpopulations
differentiated by DN stages isolated from MSNAIE Lck-Cre trans-
genic BM transplanted mice. Δ Mean fluorescence intensity (MFI)=
MFI of anti-CD30 stained sample minus MFI isotype n= 14.
d Representative flow cytometry histograms of EGFP+ lymphoma
cells of MSNAIE Lck-Cre transgenic BM transplanted mice differ-
entiated by DN stages and stained for anti-CD30. e Gene expression
levels for the indicated genes comparing CLP/DN1/DN2 and DN3/
DN4 lymphoma subpopulations. n(CLP/DN1/DN2)= 9, n(DN3/
DN4)= 6. *p < 0.05; **p < 0.01; ***p < 0.001. Data are represented
as mean+ SD.
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stage diseased animals. The observed cytological differ-
ences may also be influenced by microenvironmental dis-
tinctions. It is noteworthy that most murine mouse models
mimic hardly all features of the human counterpart disease,
but serve as important and useful platforms for under-
standing molecular and cellular mechanisms of the inves-
tigated human original.
The existence of lymphoma stem cells is supported by
several case stories, in which both -recipient and donor-
develop the same lymphoid disease after allogeneic trans-
plant. Genetic sequence homology proved the same origin
of the recipient and donor tumors [35]. Our data identify a
distinct lymphoma stem cell population, which displays
ambiguous features: while these lymphoma stem cells show
immunophenotypical features of DN3/DN4 cells, gene
expression profiles resemble primitive stem-cell-like fea-
tures. This might be caused by reprogramming of the
immunophenotypically “more differentiated” DN3/DN4
population -although still being CD4− and CD8− negative-
to a stem-cell-like origin, thereby giving this population the
capacity to robustly induce and maintain lymphoma in the
ALCL-like mouse model. In support of our data, Moti et al.,
showed the existence of a tumor-propagating cell popula-
tion in ALCL cell lines and primary ALCL patient samples,
which could not be defined solely by immunophenotyping
but shows a “stemness” gene expression profile [36]. Fur-
thermore, the authors showed in this lymphoma initiating
population a gene expression pattern that is reminiscent of
early thymic progenitors [36]. Consistent with this, Hassler
et al. demonstrated that DNA methylation patterns in ALCL
cells closely resemble that of undifferentiated thymic pro-
genitor cells [37]. These data strengthen our hypothesis that
the lymphoma stem cell population originated from the
DN3/DN4 lymphoma population, which fits to the pub-
lished concept of a thymic origin for ALCL [38, 39].
In murine thymocyte development, DN3 cells are fully
committed to the T cell lineage after transition from the
DN2 stage due to successful rearrangement of their TCR β
chain, which is associated with an invariant pre-TCR α
chain and CD3 signaling molecules forming the pre-TCR
complex. Due to β-selection, DN3 cells develop to the
DN4 stage with further maturation capacity [40]. Using a
CD4/NPM-ALK thymic T cell lymphoma model [41],
Malcolm et al. showed the importance of TCR expression
for thymic egress of tumor cells [38]. These data further
support the hypothesis that aberrant expression of TCR α/β
chains on DN lymphoma cells is important for the estab-
lishment of systemic lymphoma. In addition, analyses
of clonal TCR rearrangements in human ALCL demonstrate
major in-frame TCRα clonal rearrangements in two-thirds
of patient cases [38]. Recent analyses furthermore
support the existence of a lymphoma stem cell population,
which is able to differentiate into mature lymphoma T cell
subpopulations, as they presented similar findings in
human ALCL cell lines and primary patient samples,
demonstrating the existence of a side population with serial
tumor-propagating capacity, characterized by self-renewal-
ability and potency to differentiate to the bulk tumor
population [36].
CD30 expression is a hallmark of ALCL and is exploited
for targeted therapeutic approaches such as brentuximab
vedotin or C2NP-functionalized nanoparticles encapsulated
with doxorubicin [27, 42]. Our data demonstrate variable
CD30 expression levels within different lymphoma sub-
populations in this ALCL-like mouse model, suggesting
that the responses to anti-CD30 treatment may differ
between the lymphoma subpopulations. In particular, as the
lymphoma stem cell population demonstrates relatively low
CD30 expression, limited long-term responses of patients
treated with anti-CD30-targeted therapies may reflect the
insufficient lymphoma stem cell eradication of this
treatment.
In summary, our results highlight the existence of a
lymphoma stem cell population that originates from the
DN3/DN4 cell population in a relevant NPM-ALK positive
CD30-expressing ALCL-like mouse model, thereby pro-
viding the opportunity to test innovative treatment strategies
(e.g., NPM-ALK-/JAK-/TYK2- inhibitors) [16], which aim
to eradicate the lymphoma stem cell population and may
overcome common treatment unresponsiveness due to low
CD30 expression levels.
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